Alnylam Pharmaceuticals | ALNY - Los Gastos De Explotación

Precio De Mercado
301.30
Cambio Diario
-0.81 -0.27%
Mensual
-4.68%
Anual
14.46%
Q2 Expectativa
299.00




Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 23M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12